Key Highlights
- Can-Fite BioPharma achieved its primary safety endpoint in a Phase 2a trial testing namodenoson in patients with advanced pancreatic cancer, with zero new safety concerns identified.
- Twenty patients with heavily pretreated advanced pancreatic ductal adenocarcinoma (PDAC) participated in the clinical study.
- Approximately 33% of trial participants remained alive when data collection concluded, with ongoing survival monitoring continuing.
- The FDA has awarded namodenoson Orphan Drug Designation for treating pancreatic cancer.
- The company plans to share findings at upcoming medical conferences, where more comprehensive survival information will be available.
On March 4, 2026, Can-Fite BioPharma announced successful Phase 2a safety outcomes for namodenoson in patients with advanced pancreatic cancer. Twenty pretreated patients demonstrated excellent tolerance to the therapy, with zero new safety concerns emerging. Approximately 33% of enrolled patients were alive when data was collected, while survival tracking continues.
Namedenoson functions as a selective A3 adenosine receptor agonist. The drug targets a specific receptor found in higher concentrations within cancerous and inflammatory cells compared to healthy tissue. Can-Fite continues developing this compound for various cancer indications, with liver cancer among the targets.
The pancreatic cancer investigation used an open-label design, recruiting individuals who had experienced failure with previous systemic treatment regimens. These patients represent an especially challenging population. Pancreatic cancer ranks among cancers with the poorest survival outcomes, leaving patients who have exhausted standard therapies with minimal remaining options.
Trial participants included 20 patients displaying varied clinical characteristics, with many experiencing metastatic spread. Several individuals had undergone two or more previous treatment lines, creating a high-risk study population.
Safety served as the trial’s primary endpoint. Namodenoson successfully met this requirement. Overall survival and progression-free survival comprised secondary endpoints. Data for these measures continues to develop.
Orphan Drug Status
Namedenoson received Orphan Drug Designation from the FDA for pancreatic cancer treatment. The agency awards this classification to therapies addressing rare conditions, providing advantages such as market exclusivity periods and developmental support.
Can-Fite maintains additional namodenoson trials for advanced liver cancer. This compound represents a key pipeline asset for the organization, alongside piclidenoson, which addresses psoriasis.
Future scientific conferences will feature more comprehensive survival data presentations. The company has yet to announce specific venues or timing.
Financial Picture
Can-Fite operates as a clinical-stage biopharmaceutical company. Product sales have yet to generate substantial revenue, resulting in ongoing operational losses. The company experienced revenue decline at a -41.5% rate across the preceding three years.
Operating margin stands at -1,595%, while the Altman Z-Score reaches -26.39, indicating financial pressure. Institutional investors hold 3.49% of outstanding shares.
Market capitalization currently approximates $6.24 million, placing CANF within micro-cap territory. Shares experienced a single-day gain of +107.80% following the March 4 announcement.
The latest analyst assessment assigns CANF a Hold rating with a $0.20 price objective. This target preceded the significant stock appreciation triggered by trial news.
